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Abstract
Genome-wide association studies (GWAS) have identified 19 risk variants associated with colorectal cancer. As most of these
risk variants reside outside the coding regions of genes, we conducted cis-expression quantitative trait loci (cis-eQTL)
analyses to investigate possible regulatory functions on the expression of neighboring genes. Forty microsatellite stable and
CpG island methylator phenotype-negative colorectal tumors and paired adjacent normal colon tissues were used for
genome-wide SNP and gene expression profiling. We found that three risk variants (rs10795668, rs4444235 and rs9929218,
using near perfect proxies rs706771, rs11623717 and rs2059252, respectively) were significantly associated (FDR q-value
#0.05) with expression levels of nearby genes (,2 Mb up- or down-stream). We observed an association between the low
colorectal cancer risk allele (A) for rs10795668 at 10p14 and increased expression of ATP5C1 (q=0.024) and between the
colorectal cancer high risk allele (C) for rs4444235 at 14q22.2 and increased expression of DLGAP5 (q=0.041), both in tumor
samples. The colorectal cancer low risk allele (A) for rs9929218 at 16q22.1 was associated with a significant decrease in
expression of both NOL3 (q=0.017) and DDX28 (q=0.046) in the adjacent normal colon tissue samples. Of the four genes,
DLGAP5 and NOL3 have been previously reported to play a role in colon carcinogenesis and ATP5C1 and DDX28 are
mitochondrial proteins involved in cellular metabolism and division, respectively. The combination of GWAS findings, prior
functional studies, and the cis-eQTL analyses described here suggest putative functional activities for three of the colorectal
cancer GWAS identified risk loci as regulating the expression of neighboring genes.
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Introduction
Genome-wide association studies (GWAS) of colorectal cancer
have revealed 19 common genetic variants at 14 loci that
contribute to the risk of colorectal cancer [1,2,3,4,5,6,7]. All but
one (rs10936599) of these risk variants reside in intronic, intergenic
or gene-desert regions (Table 1) and may serve as markers for
causal variants that regulate neighboring or distant genes. Thus,
the current challenge is to elucidate how these risk variants
specifically influence the development of colorectal cancer. One
promising approach is to evaluate these variants for their
associations with differential gene expression since transcript
abundance may act as a useful intermediate phenotype in
deciphering the link between a genetic locus and a clinical
phenotype [8].
Gene expression levels are highly heritable [9,10,11] and
differential gene expression can be mapped to a particular genetic
locus as an expression quantitative trait locus (eQTL) affecting
nearby (cis-) or distant (trans-) genes [12,13]. Indeed, GWAS risk
loci have been reported to be enriched for eQTLs, providing
insight into possible mechanistic effects as well as aiding in the
identification of additional variants that can account for the
heritability of disease [14]. While several previous eQTL studies
have been conducted almost exclusively in lymphoblastoid cell
lines [12,15,16], a few recent studies have shown tissue-specific
associations between genetic variants and gene expression
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30477[17,18,19]. For cancer risk loci, the eQTL associations observed in
the originating tissue giving rise to the tumor are expected to be
more informative [20].
To uncover whether established risk variants for colorectal
cancer affect expression of neighboring genes differentially by
genotype, we conducted a cis-eQTL analysis of the GWAS-
identified colorectal risk variants using the paired colon adjacent-
normal and tumor tissue samples collected from 40 colon cancer
patients. This is the first study to conduct a cis-eQTL analysis on
both adjacent normal and tumor tissue from a homogeneous
group of molecularly characterized colorectal tumors (MSS and
CIMP-negative).
Materials and Methods
Ethics Statement
Approval for this study was obtained in accordance with local
Institutional Review Board (IRB) requirements in all participating
centers. All subjects included in this study signed an informed
written consent.
Study Subjects and Tissue Samples
Fresh-frozen, colon adenocarcinomas and paired adjacent
normal tissue samples were collected at three sites (Mayo Clinic,
Mount Sinai, and Cleveland Clinic) from participants in the
Colorectal Cancer Family Registry (C-CFR) [21] and tested for
microsatellite instability (MSI) and CpG island methylator
phenotype (CIMP). Samples from 40 microsatellite stable
(MSS)/CIMP-negative tumors, the most common form of colon
cancer, and their paired adjacent normal tissue samples (a total of
80 samples) were used for this study. The 40 patients were of
European ancestry with an average age of diagnosis of 57 years
of age.
DNA and RNA Isolation
All tumor samples were sectioned and stained with hematoxylin
and eosin, then reviewed by a pathologist to determine tumor cell
content. Tumor samples used for the study had .70% tumor cell
content. Genomic DNA and total RNA were extracted from these
tissue samples using the QIAGEN AllPrep DNA/RNA Mini kit
(QIAGEN, Valencia, CA) following manufacturer’s recommen-
dations.
MSI and CIMP Testing
MSI status was determined by assaying 10 microsatellite loci
(BAT25, BAT26, BAT40, BAT24C4, D5S346, D17S250, ACTC,
D18S55, D10S197, and MYCL) as previously described [22].
Tumors were classified as MSS if no markers exhibited instability.
For CIMP testing, tumor DNA was treated with sodium bisulfite
and analyzed using the automated real-time PCR-based Methy-
Light Assay to identify methylated CpG sites in the promoter
regions of an established five-gene panel for CIMP (CACNA1G,
IGF2, NEUROG1, RUNX3, and SOCS1) and in the promoter
region of MLH1. CIMP status was reported as previously
described in [23]. Tumors were classified as CIMP negative if
Table 1. Nineteen established CRC risk variants identified by GWAS and their proxies considered in this study.
Reference Locus SNP Position
a Closest Gene
Major Allele/
Minor Allele
b
Minor Allele
Frequency
c Proxy Used r
2d
Proxy Major
Allele/Minor
Allele
b
[18][2] 1q41 rs6691170
e 220112069 Intergenic G/T 0.36 rs11579490 0.90 C/A
[18] 1q41 rs6687758
e 220231571 Intergenic A/G 0.20 rs6691195 1.00 C/A
[18] 3q26.2 rs10936599
e 170974795 MYNN (exon) C/T 0.22 rs12638862 0.95 A/G
[22] 8q23.3 rs16892766 117699864 EIF3H A/C 0.07 - - -
[21] 8q24.21 rs6983267 128482487 Intergenic T/G 0.49 - - -
[23] 8q24.21 rs10505477 128476625 ORF DQ515897 G/A 0.50 - - -
[20] 8q24.21 rs7014346 128493974 POU5FIP1 G/A 0.37 - - -
[23] 9q24.1 rs719725
e 6355683 Intergenic A/C 0.50 rs10975552 0.97 T/C
[22] 10p14 rs10795668
e 8741225 Intergenic G/A 0.33 rs706771 0.97 G/A
[20] 11q23.1 rs3802842
e 110676919 LOC120376 (intron) A/C 0.29 rs3802840 1 G/T
[18] 12q13.13 rs7136702 49166483 Intergenic C/T 0.35 - - -
[18] 12q13.13 rs11169552
e 49441930 Intergenic C/T 0.28 rs11169544 1.00 T/C
[19] 14q22.2 rs4444235
e 53480669 BMP4 T/C 0.46 rs11623717 0.93 A/G
[22] 15q13.3 rs4779584 30782048 Intergenic C/T 0.19 - - -
[19] 16q22.1 rs9929218
e 67378447 CDH1 (intron) G/A 0.29 rs2059254 1.00 C/T
[17,20,22] 18q21.1 rs4939827
e 44707461 SMAD7 (intron) C/T 0.47 rs7226855 1.00 G/A
[19] 19q13.1 rs10411210
e,f 38224140 RHPN2 (intron) C/T 0.10 - - -
[19] 20p12.3 rs961253
e 6352281 Intergenic C/A 0.36 rs5005940 1.00 A/T
[18] 20q13.33 rs4925386 60354439 LAMA5 (intron) C/T 0.31 - - -
aPosition based on dbSNP build 130.
bMajor allele/minor allele among Europeans.
cMinor allele frequencies from published reports.
dLinkage disequilibrium between SNP and proxy in HapMap CEU.
eNot on Affymetrix 6.0 array.
fExcluded from analysis as proxy r
2,0.90.
doi:10.1371/journal.pone.0030477.t001
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gene panel and if there was no MLH1 promoter DNA methyation.
Microarray Analysis
Gene expression profiles for colon tumors and adjacent normal
tissue were evaluated with the Affymetrix GeneChip Human Exon
1.0 ST Array (Affymetrix, Santa Clara, CA); GEO Accession
number GSE31737. Ribosomal RNA (rRNA) was removed from
total RNA using the RiboMinus Human/Mouse Transcriptome
Isolation Kit (Invitrogen Carlsbad, CA). After rRNA reduction,
the Affymetrix GeneChip Whole Transcript (WT) Sense Target
Labeling Assay was used to generate amplified and biotinylated
sense-strand DNA targets for hybridization on the GeneChip
Human Exon 1.0 ST Arrays, following manufacturer’s recom-
mendations.
Genomic DNA was extracted from normal colon tissue (n=34)
or blood (n=6) samples and genotyped using the Affymetrix
Genome-Wide Human SNP 6.0 Array. In brief, DNA samples
were processed, labeled and hybridized according to the
manufacturer’s recommendations. All arrays were scanned on
The GeneChipH Scanner 3000 7G using the Affymetrix
GeneChip Command Console (AGCC) Software to measure the
fluorescent signal intensities at each probe location. The average
call rate for the 80 samples was 99.6%.
Selection of risk variants for CRC
We considered all 19 established risk variants for colorectal
cancer reported by genome-wide association studies through
November, 2010 (Table 1) [1,2,3,4,5,6,7]. Genotype data for 12 of
the 19 variants were not available from the Affymetrix 6.0 array
(Table 1). For each of these 12 variants not on the array, a proxy
was selected among the typed SNPs within a region 20 kb up- or
downstream of the risk allele, which was in highest LD (r
2$0.90)
with the risk variant among HapMap CEU (http://gvs.gs.
washington.edu/GVS/). Because rs10411210 at 19q13.1 did not
have an acceptable proxy (r
2,0.90) on the Affymetrix 6.0 array, it
was excluded, resulting in a total of 18 risk variants for analysis.
Real-Time PCR Validation
Technical validation of gene expression profiles was performed
on 20 tumor-adjacent normal pairs included in the microarray
assays. Real-Time quantitative PCR (qPCR) was conducted for
the genes found to be differentially expressed by geneotype in this
study (ATP5C1, DLGAP5, NOL3, DDX28) and for four genes (APC,
MACC1, DCC, and DSC2) previously identified to be differentially
expressed in colorectal tumors. Briefly, cDNA was prepared from
up to 2 mg of untreated total RNA using High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems Foster City, CA).
For Real-Time qPCR, 21–25 ng of cDNA (based on RNA input)
was run on 384-well PCR plates in triplicate using 16 TaqMan
gene expression assays and TaqMan Universal PCR Mastermix
with the recommended thermal profiles on the 7900HT Fast Real-
Time PCR System (Applied Biosystems Foster City, CA).
Statistical Analysis
For each of the 18 risk variants examined, a cis-eQTL analysis
was performed to investigate the association between SNP
genotypes and gene expression of all nearby genes (within 2 Mb
up- and downstream of each SNP). Each SNP was examined by
co-dominant and dominant models, using the reported major
allele among Europeans as the reference allele. Risk variants
having a genotype category with less than 2 samples are not
presented. Genome-wide gene expression values were log2-
transformed and normalized using Robust Multi-array Analysis
(RMA), using median polish summarization [24]. The transcript
expression value for each gene considered was based on the mean
of the probeset intensity for that gene. To identify cis-genes
associated with differential expression by SNP genotype, multi-
variate analysis of covariance (ANCOVA) was conducted,
adjusting for tumor stage and assay batch. The Benjamini and
Hochberg’s false discovery rate (FDR) correction was applied to
correct for the number of genes tested within the 4 Mb interval
surveyed for each risk allele [25]. Spearman rank correlation
testing was conducted to validate the correlation between
microarray and qPCR assays. The Partek Genomics Suite 6.5
Software (St. Louis, MO) was used for microarray and statistical
data analyses.
Results
In our sample set of 40 paired MSS and CIMP-negative
colorectal tumors and adjacent normal tissues, we identified 50
genes that were differentially expressed by genotype for 11 of the
18 risk variants studied (p-values ,0.05; Table S1). After
correcting for multiple-testing, four genes (ATP5C1, DLGAP5,
NOL3, DDX28) were identified to demonstrate a statistically
significant difference in expression levels in the tumor or adjacent
normal colon tissue in one or more of the three genotype
categories for rs10795668 (10p14), rs4444235 (14q22.2), or
rs9929218 (16q22.1) (global test: FDR q-value,0.05; Table 2).
For rs10795668 at 10p14, we observed a significant difference in
gene expression levels by genotype in tumors for the gene
encoding for the gamma subunit in the F1 complex of
mitochondrial ATP synthase (ATP5C1; q-value=0.024). In
contrast, there was no difference in gene expression levels by
genotype for ATP5C1 or other neighboring genes in adjacent
normal colon tissue for this variant. Similarly, for rs4444235 at
14q22.2, we observed a significant difference in gene expression
levels by genotype for the Drosophila homolog of discs, large
associated protein 5 (DLGAP5; q-value=0.041) when comparing
gene expression levels in tumor tissue, but not in adjacent normal
tissue. For rs9929218 at 16q22.1, two genes were observed to have
a difference in expression levels by genotype: nucleolar protein 3
(NOL3; q-value=0.017) and DEAD box polypeptide 28 (DDX28,
q-value=0.046), in adjacent normal but not tumor tissue.
The genotype-specific comparisons for the three risk variants
with cis-eQTL associations are shown in Table 2 and Figure 1. We
observed a statistically significant increased expression of ATP5C1
in the tumors of patients homozygous for the A allele (q-
value=0.006) at rs10795668 (10p14) compared to the reference
genotype (GG). For rs4444235 (14q22.2), tumors of patients who
were homozygous for the C allele had significantly higher
expression for DLGAP5 in comparison to the tumors of those
with the reference genotype (TT) (q-value=0.014). For rs9929218
(16q22.1), the genotype specific expression for NOL3 and DDX28
in the adjacent normal colon tissue were significantly decreased
among patients heterozygous for the A allele versus those with the
reference genotype (GG) (q-value=9.34610
25 and q-val-
ue=4.15610
24, respectively).
Due to the small number of subjects who were homozygous for
the colorectal cancer minor alleles, we also considered gene
expression levels in samples that carried either one or two copies of
the minor allele, in comparison to the reference genotype (last
column of Table 2). Tumor samples from patients with one or two
copies of the minor allele(s) (any A) for rs10795668, compared to
the GG genotype, demonstrated increased expression of ATP5C1
at 10p14 (q-value=0.004). Similarly, for the tumor samples of
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rs4444235 (14q22.2), expression of DLGAP5 was increased in
comparison to tumors with the TT genotype (q-value=0.032).
There was no statistically significant difference in the expression of
NOL3 and DDX28 in tumor or adjacent normal tissue when
comparing patients with one or two copies of the minor allele(s) (A)
versus those with the GG genotype for rs9929218 at 16q22.1
(Table 2).
The four genes that we identified to be differentially expressed
in relation to the three risk variants have been shown to have a
role in cancer-related mechanisms, such as cellular metabolism
and proliferation, and apoptosis [26,27,28,29]. Therefore, we
compared the expression levels of the four cis-regulated genes
(ATP5C1, DLGAP5, DDX28, NOL3) between tumors and adjacent
normal colon tissue. All four genes were differentially expressed in
tumors compared to the adjacent normal colon tissue samples.
The expression level of ATP5C1 (p-value=0.005) was lower in
tumors, whereas the expression levels of DLGAP5 (p-val-
ue=7.80610
27), DDX28 (p-value=0.016) and NOL3 (p-value
0.044) were higher in tumors compared to adjacent normal colon
tissue (Figure 2).
To confirm the reliability of the microarray results, we
conducted a technical validation using qPCR testing of gene
expression levels on 20 cases with remaining RNA, out of the 40
original cases, for both adjacent normal and tumor tissue samples.
The Spearman’s Rank Order correlation coefficients for the four
genes identified in the cis-eQTL analysis in the tissue type (tumor
or normal) where genotype-specific differential expression was
observed were, ATP5C1 rs=0.39; DLGAP5 rs=0.68; NOL3
rs=0.11; DDX28 rs=0.22. As an additional technical validation
step, we assayed four genes (APC, MACC1, DCC, and DSC2) that
have been previously established to be differentially expressed
between tumor and adjacent normal tissue in colorectal cancer
[30,31,32,33]. We found good correlation (Spearman’s Rank
Order correlation, rs.0.5) in the gene expression profiles for all
four genes between our microarray and qPCR assays. Specifically,
lower expression of APC, DCC, and DSC2 and higher expression of
MACC1 was observed in the tumor samples relative to the paired
Figure 1. Expression of four genes found to differ by genotype for three colorectal cancer risk variants. Box plots of normalized gene
expression levels of ATP5C1, DLGAP5, NOL3, and DDX28 for paired adjacent normal colon tissue (n=40) and colon tumor tissue (n=40). Each point
represents the normalized RNA expression levels for an individual. The median gene expression level for each genotype specific group is indicated by
a line inside each box within the graph. The p-value indicates the significance of the global test comparing expression across genotypes. If the
p-values were significant (p-value#0.05), the FDR q-values were provided, indicating the significance after correction for multiple comparisons.
doi:10.1371/journal.pone.0030477.g001
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These technical validation data support the reliability of our
observations based on the gene expression microarray results.
Discussion
Our study examined 18 of the 19 GWAS-identified colorectal
cancer risk variants for association with the expression of
neighboring genes (within 2 Mb up- and downstream of the
SNP) in 40 patients with MSS and CIMP-negative colon cancer,
using fresh-frozen paired adjacent normal and colon tumor
samples (Figure S1). We identified four genes (ATP5C1, DLGAP5,
NOL3, and DDX28) at three risk loci with a statistically significant
difference in gene expression levels by genotype.
ATP5C1 encodes the gamma subunit of the catalytic core (F1) of
the mitochondrial ATP synthase, the enzyme complex responsible
for ATP synthesis, known to play a central role in cellular
respiration. A common event in tumor cells is the metabolic switch
from respiration (in the mitochondria) to glycolysis (in the cytosol),
often referred as ‘‘the Warburg effect’’ [34,35]. Multiple
Figure 2. Tumor versus adjacent normal gene expression profiles of the cis-eQTL associated genes. Box plots of gene expression levels
for ATP5C1, DLGAP5, NOL3, and DDX28 in paired adjacent normal colon tissue and colon tumor tissue (n=40 pairs). The significance of differential
expression is indicated by the p-value.
doi:10.1371/journal.pone.0030477.g002
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the expression of the beta subunit of ATP synthase (F1) (ATP5B),
leading to the disruption of the catalytic function of the ATP
synthase complex, an event that has been previously observed in
multiple cancer types [26,29]. In the tumor samples analyzed in
the present study, we observed an increase in the expression levels
of ATP5C1 that was significantly associated with the A allele at
rs10795668. The A allele has been associated with a decreased risk
of colorectal cancer (OR=0.89; p=2.5610
213) in a previous
GWAS [6]. Thus, the increased expression of ATP5C1 associated
with the A allele would be consistent with maintaining the
activities of ATP synthase and cellular respiration and potentially
inhibiting tumor progression for colorectal cancer.
DLGAP5, also known as HURP (hepatoma up-regulated
protein), encodes a microtubule binding protein involved in the
formation and function of mitotic spindles [36,37] and is believed
to be a cell cycle regulator and target of the Aurora A kinase
[38,39]. Over-expression of DLGAP5 has been associated with the
deregulation of spindle fiber formation and function during mitosis
[38]. In addition, it has been reported that DLGAP5 may have a
role in stem cell maintenance and survival and has been observed
to be over-expressed in colorectal cancer cells [27,28,40]. The C
allele for rs4444235 has been previously reported in GWAS to
increase the risk of colorectal cancer (OR=1.11; p=8.1610
210)
[3]. Our finding that the C allele is associated with increased
DLGAP5 expression in tumors, suggests a potential mechanism by
which this allele may promote tumor progression for colorectal
cancer. In addition, we note that rs4444235 has been shown to
have a significantly stronger association with MSS-subtypes of
colorectal cancer [3], which was the molecular subtype of the
tumor samples included in our study.
DDX28 encodes for a DEAD box protein with RNA helicase
activity. Although DDX28 has not specifically been reported to
have a role in colorectal cancer, other DEAD box RNA helicases
have been shown to be overexpressed in colorectal tumors,
demonstrating a function for RNA helicases in tumorigenesis
[41,42,43]. The NOL3 gene, also known as ARC (apoptosis
repressor with caspase recruitment domain) encodes for an anti-
apoptotic protein that regulates p53 and caspases 2 and 8 [44,45].
Several studies have shown that NOL3 is regulated by activated N-
and H- Ras and is overexpressed in colorectal cancer [41,46,47].
We also observed NOL3 to be overexpressed in the tumor versus
adjacent normal tissue. In addition, our cis-eQTL analysis
indicated an association for decreased expression of both DDX28
and NOL3 in adjacent normal colon tissues of individuals carrying
the A allele, particularly cases with the GA genotype for
rs9929218. Taken together with the finding that the A allele at
rs9929218 is associated with decreased risk of colorectal cancer
(OR=0.91; p=1.2610
28) [3], our observation of an association
between this allele and decreased DDX28 and NOL3 expression in
adjacent normal tissue suggests that these genes may lower risk of
colorectal cancers by functioning to inhibit early events of
colorectal carcinogenesis. Our findings may also underline the
importance of studying normal tissue, in addition to tumor tissue,
in eQTL studies of cancer.
Interestingly, the differentially expressed genes identified in this
study were not genes directly neighboring the GWAS risk variants.
For example, for rs10795668, GATA3 is the closest neighboring
gene, but we did not observe any significant association for
differential expression of GATA3 and this SNP’s genotype (p-
value.0.05). Similarly, for rs4444235 and BMP4, which are
separated by less than 10 kb, and for rs9929218 which is located in
an intron of CDH1, we observed no association with genotype and
gene expression. In a recent study, Carvajal-Carmona et al.
reported on a fine mapping study to colorectal cancer risk alleles at
8q23.3 and 16q22.1 [48]. They also found no association with
gene expression of the nearest gene, such as EIF3H and CDH1 in
monocyte cell lines, respectively, but find an association with more
distant genes such as UTP23 for rs16892766 at 8q23.3 and ZFP90
for rs2059254 at 16q22.1 [48]. In our study of colon tissue
samples, we also observed an association (p=0.03) for ZFP90
expression levels and the risk allele at 16q22.1 (Table S1); however
the association was no longer significant after adjustments for
multiple comparisons. These results, and those of other studies
[3,12,15,49], suggest that risk variants may not preferentially
regulate genes that are closest. Rather, transcriptional regulatory
mechanisms impacted by allelic status may involve complex
chromatin confirmation states and function within a tissue specific
context.
Few other studies have examined the relationship between
colorectal cancer risk variants and gene expression in near-by
genes. The COGENT study investigated six GWAS risk variants
for their effect on the expression of a small number of neighboring
candidate genes in 90 CEU Hapmap, EBV-transformed lympho-
blastoid cell lines (rs9929218 for CDH1 and CDH3, rs4444235 for
BMP4, rs10411210 for RHPN2, rs961253 for BMP2, rs6983267
for c-MYC, and rs3802842 for LOC120376) [3]. No significant
associations were found. Although we were not able to evaluate
rs10411210, we similarly found no associations between the
remaining four variants and differential expression of these genes
before or after correction for multiple testing in both adjacent
normal colon and tumor tissue (p-values.0.05). In addition,
similar to our findings, a previous study of rs6983267 found no
association with c-MYC expression in 117 samples of normal colon
tissue [50].
This is the most comprehensive and one of the largest tissue-
specific cis-eQTL studies reported to date for colorectal cancer.
Nonetheless, the interpretation of our results is constrained by our
limited statistical power (,60% to detect a 15% difference in
expression across genotypes) and the need for replication studies
with larger sample sizes to confirm the effect of these risk variants
on regulating gene expression of neighboring genes. The most
notable strengths of this study were the inclusion of both adjacent
normal and malignant tissue and the restriction to a homogeneous
group of molecularly characterized colorectal tumors (MSS and
CIMP-negative).
In summary, our data indicate that the analysis of the effects of
risk alleles on gene expression in well-characterized tumors and
their paired adjacent normal tissue is likely to be highly
informative. Further examination of the risk variants and
differentially expressed genes will need to be carried out to
confirm our results, as well as expanding the analysis to other
molecular subtypes of colorectal cancer and addressing mecha-
nistic events in a tissue specific context.
Supporting Information
Figure S1 Flow chart of cis-eQTL analysis of colorectal
cancer risk variants. The flow chart outlines the procedures to
analyze of the effects of risk alleles on gene expression, of genes
within a 4 Mb range of the risk allele, in well-characterized
colorectal tumors and their paired adjacent normal tissue.
(TIF)
Table S1 Differentially expressed genes associated with
risk variants for colorectal cancer. A list of the 50 genes that
were identified to be differentially expressed by genotype for 11 of
the 18 risk variants studied (p-values,0.05) in the analysis of 40
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